Studies of in-hospital blood pressure elevations have primarily reported the acute effects of treatment on the blood pressure rather than clinical outcomes. For example, in a study of medical inpatients with asymptomatic hypertension, hydralazine or labetalol given orally or intravenously acutely reduced blood pressure in 85% of patients. In 22% the systolic blood pressure was reduced by at least 25% within six hours.12 Such an acute and excessive reduction in blood pressure could decrease cerebral and myocardial perfusion. This approach should be avoided except in particular circumstances such as hypertensive emergencies with end-organ damage (e.g. aortic dissection or acute renal failure).13,14 Clinical features of hypertensive emergencies may include chest pain, severe headache, confusion, blurred vision, nausea and vomiting, severe anxiety, dyspnoea, seizures and reduced consciousness. Papilloedema is a hallmark of malignant hypertension and can be seen on examination of the optic fundi.
Outcomes
Observational studies published since 2018 have reported the effect on clinical end points of starting or increasing antihypertensive treatment in hospital. One study reported that 14% of older patients admitted for non-cardiac reasons were discharged with new or intensified antihypertensive treatment. Among those who started treatment, 29% received renin–angiotensin system inhibitors, 42% beta blockers, 27% calcium-channel blockers, 11% thiazide diuretics and 12% other antihypertensives. More than half (52%) of the patients whose treatment was intensified had well-controlled blood pressure before admission. The probability of antihypertensive intensification was 25% for patients with moderately elevated blood pressure and 42% for those with severe elevations.7
In another study, patients discharged with a new or intensified antihypertensive regimen were more likely to be readmitted (hazard ratio (HR) 1.23, 95% confidence interval (CI) 1.07–1.42, number needed to harm (NNH) 27, 95% CI 16–76) or experience serious adverse events within 30 days (HR 1.41, 95% CI 1.06–1.88, NNH 63, 95% CI 34–370). In secondary analyses, new or intensified inpatient treatment was associated with an increased risk of cardiovascular events within 30 days of discharge (HR 1.65, 95% CI 1.13–2.40).15
The association between inpatient treatment initiation or intensification and specific end points was studied in 22,834 adults admitted with non-cardiac diagnoses at 10 hospitals in the USA. At least one hypertensive reading was recorded in 78% of patients. Of these, 33% were treated mainly with oral antihypertensives. After controlling for patient and blood pressure characteristics, treatment was associated with an increased risk of in-hospital acute kidney injury (odds ratio (OR) 1.36, 95% CI 1.21–1.52) and myocardial injury (OR 2.23, 95% CI 1.56–3.20). By contrast, there were no significant differences in the risk of in-hospital stroke, length of stay, myocardial infarction within 30 days and blood pressure control one year after discharge.16
A cohort study matched 4219 patients admitted without a primary cardiovascular diagnosis who received antihypertensive drugs on an as-needed basis, in addition to scheduled antihypertensives, with 4219 patients who only received scheduled antihypertensives. The former group had an increased risk of an abrupt lowering of systolic blood pressure by more than 25% within one hour of administration (OR 2.05, 95% CI 1.56–2.71), acute kidney injury
(OR 1.24, 95% CI 1.09–1.42), ischaemic stroke (OR 8.5,
95% CI 1.96–36.79), death (OR 2.36, CI 1.26–4.41), and
prolonged hospitalisation (4.7 vs 2.9 days). Ischaemic events were more frequent with abrupt blood pressure reductions and more doses of as-needed drugs. Notably, 93% of the as-needed drugs were given intravenously, with hydralazine (53%) and labetalol (43%) being the most common drugs.17
The results of these observational studies, primarily conducted in the USA, suggest that proactively managing asymptomatic in-hospital blood pressure elevations does not confer clear benefits. Treatment may be associated with significant adverse outcomes, at least in the short term.